N-[3-(6-methyl-pyridin-3-yl)acryloyl]-4-(4-diphenylmethyl-1-piperazinyl)butylamine | 118420-47-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[3-(6-methyl-pyridin-3-yl)acryloyl]-4-(4-diphenylmethyl-1-piperazinyl)butylamine
• 英文别名: N-<4-<4-(Diphenylmethyl)-1-piperazinyl>butyl>-3-(6-methyl-3-pyridyl)acrylamide；(E)-N-<4-(4-diphenylmethyl-1-piperazinyl)butyl>-3-(6-methyl-3-pyridyl)acrylamide；N-<4-(4-diphenylmethyl-1-piperazinyl)butyl>-3-(6-methyl-3-pyridyl)acrylamide；tagorizine；AL3264；N-[3-(6-methyl-3-pyridyl)acryloyl)-4-(4-diphenyl-methyl-1-piperazinyl)butylamine；(E)-N-[4-(4-benzhydrylpiperazin-1-yl)butyl]-3-(6-methylpyridin-3-yl)prop-2-enamide
• CAS: 118420-47-6
• 化学式: C₃₀H₃₆N₄O
• 分子量: 468.642
• InChiKey: DVYCNKDRINREMB-WUKNDPDISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  35
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  48.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5-甲酰基-2-甲基吡啶 在 哌啶 、 三乙胺 作用下， 以 四氢呋喃 、 吡啶 为溶剂， 反应 1.0h， 生成 N-[3-(6-methyl-pyridin-3-yl)acryloyl]-4-(4-diphenylmethyl-1-piperazinyl)butylamine
  参考文献：
  名称：

  Acrylamide derivatives as antiallergic agents. 2. Synthesis and structure activity relationships of N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(3-pyridyl)acrylamides

  摘要：

  A new series of 3-(3-pyridyl)acrylamides 16, 17, 19, and 26, and 5-(3-pyridyl)-2,4-pentadienamides 20-25 were prepared and evaluated for their antiallergic activity. Several of these compounds exhibited more potent inhibitory activities than the parent compound 1a [(E)-N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3- (3-pyridyl)acrylamide] against the rat passive cutaneous anaphylaxis (PCA) reaction and the enzyme 5-lipoxygenase. Particularly, (E)-N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3- (6-methyl-3-pyridyl)acrylamide (17p) showed an ED50 value of 3.3 mg/kg po in the rat PCA test, which was one-fifth of ketotifen and oxatomide. As compared with ketotifen and oxatomide, compound 17p (AL-3264) possessed a better balance of antiallergic properties due to inhibition of chemical mediator release, inhibition of 5-lipoxygenase, and antagonism of histamine.

  DOI：

  10.1021/jm00123a012

文献信息

• 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists
  申请人：——

  公开号：US20010046993A1

  公开（公告）日：2001-11-29

  This invention provides a compound of the formula (I): 1 or the pharmaceutically acceptable salts thereof wherein A is independently halo; Y 1 is —(CH 2 ) m —, C(O) or S(O); Y 2 is N or CH; R 1 and R 2 are independently C 1-4 alkyl; R 3 is selected from the following: (a) optionally substituted —(CH 2 ) p —C 3-7 cycloalkyl; (b) optionally substituted —C 5-7 alkyl; and (c) substituted —C 1-4 alkyl; and (d) optionally substituted C 7- bicycloalkyl; R 4 is optionally substituted thiazolyl, imidazolyl or oxazolyl; X is S, —NH, —N—C 1-4 alkyl or O; R 5 is hydrogen or C 1-4 alkyl; R 6 is C 1-4 alkyl or halo; m is 0, 1 or 2; n is 0, 1, 2, 3, 4 or S; and p is 0, 1, 2, 3, 4, 5 or 6. These compounds are useful for the treatment of medical conditions caused by bradykinin such as inflammation, cardiovascular disease, pain, etc. This invention also provides a pharmaceutical composition comprising the above compound.

  这项发明提供了以下式(I)的化合物或其药学上可接受的盐，其中A独立地是卤素；Y1是—(CH2)m—、C(O)或S(O)；Y2是N或CH；R1和R2独立地是C1-4烷基；R3从以下选项中选择：(a) 可选地取代的—(CH2)p—C3-7环烷基；(b) 可选地取代的—C5-7烷基；以及(c) 取代的—C1-4烷基；和(d) 可选地取代的C7双环烷基；R4是可选地取代的噻唑基、咪唑基或噁唑基；X是S、—NH、—N—C1-4烷基或O；R5是氢或C1-4烷基；R6是C1-4烷基或卤素；m是0、1或2；n是0、1、2、3、4或S；p是0、1、2、3、4、5或6。这些化合物可用于治疗由激肽酶引起的医疗状况，如炎症、心血管疾病、疼痛等。该发明还提供了包含上述化合物的药物组合物。
• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
• Substituted 1,4-dihydropyridine compounds as bradykinin antagonists
  申请人：——

  公开号：US20020042421A1

  公开（公告）日：2002-04-11

  This invention provides a compound of the formula (I): 1 or the pharmaceutically acceptable salts thereof wherein A is independently halo; Y is —(CH 2 ) m— , —C(O)— or —S(O)—; R 1 and R 2 are independently C 1-4 alkyl; R 3 is C 7-9 bicycloalkyl, C 5-7 azacycloalkyl or C 7-9 azabicycloalkyl, the C 7-9 bicycloalkyl, C 5-7 azacycloalkyl or C 7-9 azabicycloalkyl being optionally substituted with one, two or three substituents are independently selected from oxo, hydroxyl, C 1-4 alkyl, C 1-4 alkyloxy, C 1-4 alkyl-carbonyl, formyl, C 1-4 alkylenedioxy, and phenyl-C 1-4 alkyl; R 4 is thiazolyl, imidazolyl or oxazolyl, the thiazolyl, imidazolyl or oxazolyl being optionally substituted with one or two substituents independently selected from C 1-4 alkyl and halo; R 5 is hydrogen or C 1-4 alkyl;m is 0, 1 or 2; and n is 0, 1, 2, 3, 4 or 5. These compounds are usefuil for the treatment of medical conditions mediated by bradykinin such as inflammation, allergic rhinitis, pain, etc. This invention also provides a pharmaceutical composition comprising the above compound.

  这项发明提供了以下式（I）的化合物或其药学上可接受的盐，其中A独立表示卤素；Y为—（CH2）m—，—C(O)—或—S(O)—；R1和R2独立表示C1-4烷基；R3为C7-9双环烷基，C5-7杂环烷基或C7-9杂双环烷基，其中C7-9双环烷基，C5-7杂环烷基或C7-9杂双环烷基可以选择性地被一个、两个或三个取代基取代，这些取代基独立地选自氧代、羟基、C1-4烷基、C1-4烷氧基、C1-4烷基羰基、甲酰基、C1-4烷基二氧基和苯基-C1-4烷基；R4为噻唑基、咪唑基或氧唑基，其中噻唑基、咪唑基或氧唑基可以选择性地被一个或两个取代基独立地选自C1-4烷基和卤素取代；R5为氢或C1-4烷基；m为0、1或2；n为0、1、2、3、4或5。这些化合物可用于治疗由激肽酶介导的医疗状况，如炎症、过敏性鼻炎、疼痛等。这项发明还提供了包含上述化合物的药物组合物。
• N-benzenesulfonyl l-proline compounds as bradykinin antagonists
  申请人：Pfizer Inc.

  公开号：US20020128271A1

  公开（公告）日：2002-09-12

  This invention provides a compound of the formula (I): 1 or the pharmaceutically acceptable salts thereof wherein X 1 and X 2 are halo; R 1 and R 2 are independently hydrogen or C 1-4 alkyl; R 3 and R 4 are each hydrogen or halo; and R 5 is (a) —C 3-9 diazacycloalkyl optionally substituted with C 5-11 azabicycloalkyl; (b) —C 3-9 azacycloalkyl-NH—(C 5-11 azabicycloalkyl optionally substituted with C 1-4 alkyl); (c) —NH—C 1-3 alkyl-C(O)—C 5-11 diazabicycloalkyl; (d) —NH—C 1-3 alkyl-C(O)—NH—C 5-11 azabicycloalkyl, the C 5-11 azabicycloalkyl being optionally substituted with C 1-4 alkyl; (e) —C 3-9 azacycloalkyl optionally substituted with C 3-9 azacycloalkyl; or (f) —NH—C 1-5 alkyl-NH—C(O)—C 4-9 cycloalkyl-NH 2 . These compounds are useful for the treatment of medical conditions mediated by bradykinin such as inflammation, allergic rhinitis, pain, etc. This invention also provides a pharmaceutical composition comprising the above compound.

  这项发明提供了式(I)的化合物：1或其药学上可接受的盐，其中X1和X2是卤素；R1和R2分别是氢或C1-4烷基；R3和R4分别是氢或卤素；以及R5是(a) -C3-9二氮杂环烷基，可选择地取代为C5-11氮杂双环烷基；(b) -C3-9氮杂环烷基-NH-(可选择地取代为C1-4烷基的C5-11氮杂双环烷基)；(c) -NH-C1-3烷基-C(O)-C5-11二氮杂双环烷基；(d) -NH-C1-3烷基-C(O)-NH-C5-11氮杂双环烷基，C5-11氮杂双环烷基可选择地取代为C1-4烷基；(e) -C3-9氮杂环烷基，可选择地取代为C3-9氮杂环烷基；或(f) -NH-C1-5烷基-NH-C(O)-C4-9环烷基-NH2。这些化合物对于治疗由激肽酶介导的医疗状况如炎症、过敏性鼻炎、疼痛等是有用的。这项发明还提供了包含上述化合物的药物组合物。
• Pharmaceutical preparation comprising an active dispersed on a matrix
  申请人：——

  公开号：US20040058896A1

  公开（公告）日：2004-03-25

  The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.

  本发明涉及制药技术领域，描述了一种新的有利的活性成分制备方法。这种新的制备方法适用于生产大量的药物剂型。在这种新的制备方法中，活性成分基本上均匀地分散在由脂肪醇、甘油三酯、部分甘油酯和脂肪酸酯等多种赋形剂中选择的一种或多种赋形剂组成的赋形剂基质中。